Compare KEN & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KEN | VRDN |
|---|---|---|
| Founded | 2014 | 2006 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Medical Specialities |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.2B |
| IPO Year | N/A | N/A |
| Metric | KEN | VRDN |
|---|---|---|
| Price | $79.32 | $27.81 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $41.42 |
| AVG Volume (30 Days) | 14.6K | ★ 1.4M |
| Earning Date | 04-01-2026 | 02-27-2026 |
| Dividend Yield | ★ 6.06% | N/A |
| EPS Growth | ★ 177.70 | N/A |
| EPS | ★ 8.96 | N/A |
| Revenue | ★ $803,304,000.00 | $70,789,000.00 |
| Revenue This Year | N/A | $26,080.80 |
| Revenue Next Year | N/A | $2.07 |
| P/E Ratio | $8.54 | ★ N/A |
| Revenue Growth | 8.15 | ★ 23340.07 |
| 52 Week Low | $27.10 | $9.90 |
| 52 Week High | $79.48 | $34.29 |
| Indicator | KEN | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 67.62 | 34.99 |
| Support Level | $71.30 | $28.44 |
| Resistance Level | $79.48 | $30.50 |
| Average True Range (ATR) | 1.69 | 1.47 |
| MACD | 0.27 | -0.41 |
| Stochastic Oscillator | 87.18 | 7.29 |
Kenon Holdings Ltd is a holding company that operates dynamic, growth-oriented businesses. The company's operating segments include OPC Power Plants, CPV Group, and ZIM. It generates maximum revenue from the OPC Power Plants segment, which generates and supplies electricity and energy in Israel. CPV Group is a limited partnership owned by OPC, which generates and supplies electricity and energy in the United States. Geographically, the company generates a majority of its revenue from Israel and the rest from the United States.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).